Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

(2020) Abishek Chandrashekar et al.   SCIENCE

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

(2020) Jingyou Yu et al.   SCIENCE

Immunogenicity of a DNA vaccine candidate for COVID-19

(2020) Trevor R. F. Smith et al.   Nature Communications

Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers

(2020) Lucy Rutten et al.   Cell Reports

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

(2020) Noe B. Mercado et al.   NATURE

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice

(2020) Leslie van der Fits et al.   npj Vaccines

Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

(2020) Ariane Sternberg et al.   LIFE SCIENCES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya

(2019) Gaudensia Mutua et al.   JOURNAL OF INFECTIOUS DISEASES

Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation

(2018) Pan Liu et al.   KIDNEY INTERNATIONAL

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

(2018) Dan H Barouch et al.   LANCET

A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers

(2018) Lucy Rutten et al.   Cell Reports

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

(2018) Robert N. Kirchdoerfer et al.   Scientific Reports

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year

(2017) Rebecca L. Winslow et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

(2017) Jesper Pallesen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural basis for antibody-mediated neutralization of Lassa virus

(2017) Kathryn M. Hastie et al.   SCIENCE

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

(2017) Naif Khalaf Alharbi et al.   VACCINE

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein

(2017) Michael B. Battles et al.   Nature Communications

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention

(2016) Lindsey R. Baden et al.   ANNALS OF INTERNAL MEDICINE

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

(2016) Iain D. Milligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

(2016) Georgi Shukarev et al.   Human Vaccines & Immunotherapeutics

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

(2015) Anders Krarup et al.   Nature Communications

Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine

(2014) N. Iwata-Yoshikawa et al.   JOURNAL OF VIROLOGY

Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology

(2014) Yoshikazu Honda-Okubo et al.   JOURNAL OF VIROLOGY

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

(2012) Lindsey R. Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)

(2012) Dan H. Barouch et al.   JOURNAL OF INFECTIOUS DISEASES

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One

Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species

(2012) Roland Zahn et al.   PLoS One

The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert

(2010) K. Radosevic et al.   Clinical and Vaccine Immunology

Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys

(2008) J. Liu et al.   JOURNAL OF VIROLOGY

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

(2008) Julie E. Martin et al.   VACCINE